Organigram Holdings Tuesday Brief: BAT Partnership and International Medical Sales Define Canadian LP Thesis Into Q3 2026

TL;DR: Organigram Holdings (NASDAQ: OGI; TSX: OGI) closes Q2 2026 with a differentiated Canadian LP profile anchored by its BAT-backed research program and expanding international medical revenue. As the sector awaits DEA finalization of Schedule III rescheduling, OGI’s capital-light growth strategy and cross-border positioning offer institutional investors a distinct risk-reward profile relative to U.S. MSO […]

Trulieve Cannabis Monday Brief: Florida Market Leadership and 280E Relief Position Southeast MSO for Q3 2026 Inflection

TL;DR: Trulieve Cannabis (TCNNF) enters Q3 2026 as Florida’s dominant cannabis operator, with the state’s adult-use market expansion representing the most significant near-term volume catalyst for a company whose vertically integrated footprint was built expressly for the Florida regulatory environment. The approaching resolution of the Section 280E federal tax burden under Schedule III rescheduling represents […]

📅 Yesterday's News & Older Articles →